Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy

$1.46bn Deal Biggest Ever In Korean Biopharma

Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.

botulinum toxin
GS-CBC Consortium Becomes Largest Shareholder Of Hugel • Source: Alamy

A multinational consortium including Korean conglomerate GS Group has become the largest shareholder of major medical aesthetics firm Hugel Pharma Co, Ltd, marking the biggest ever biopharma acquisition in South Korea.

Through the deal, worth KRW1.7tn ($1.46bn), Hugel’s largest shareholder Leguh Issuer Designated Activity Company (LIDAC), part of Bain Capital, has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia